GlassScriptPhysician profile
Mary Tompkins
NPI 1396274445
$858.17
in general payments reported to CMS, 2019-2025
16 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.61 · 2022: $182 · 2023: $115 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $115.20 | 2023 | Calquence |
| Blueprint Medicines Corporation | $100.56 | 2022 | |
| Antares Pharma, INC. | $85.61 | 2025 | Xyosted |
| Myovant Sciences INC. | $81.49 | 2022 | |
| Merck Sharp & Dohme LLC | $72.60 | 2025 | Keytruda, Lynparza |
| Alnylam Pharmaceuticals INC. | $60.64 | 2025 | Givlaari |
| Abbvie INC. | $55.94 | 2021 | |
| Janssen Biotech, INC. | $54.26 | 2025 | Erleada |
| Tolmar, INC. | $47.61 | 2025 | Jatenzo, Eligard |
| Urogen Pharma, INC. | $36.16 | 2025 | |
| Dendreon Pharmaceuticals LLC | $34.92 | 2025 | Provenge |
| 180 Medical, INC. | $29.30 | 2025 | |
| Endo USA, INC. | $24.73 | 2025 | Aveed |
| Ferring Pharmaceuticals INC. | $23.19 | 2025 | Adstiladrin |
| Pfizer INC. | $18.29 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Tompkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.